Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial
Background Alzheimer disease (AD) may be caused by the toxic accumulation of β-amyloid
(Aβ). Objective To test this theory, we developed a clinical intervention using clioquinol, a
metal-protein–attenuating compound (MPAC) that inhibits zinc and copper ions from binding
to Aβ, thereby promoting Aβ dissolution and diminishing its toxic properties. Methods A pilot
phase 2 clinical trial in patients with moderately severe Alzheimer disease. Results Thirty-six
subjects were randomized. The effect of treatment was significant in the more severely …
(Aβ). Objective To test this theory, we developed a clinical intervention using clioquinol, a
metal-protein–attenuating compound (MPAC) that inhibits zinc and copper ions from binding
to Aβ, thereby promoting Aβ dissolution and diminishing its toxic properties. Methods A pilot
phase 2 clinical trial in patients with moderately severe Alzheimer disease. Results Thirty-six
subjects were randomized. The effect of treatment was significant in the more severely …